Trevena, Inc. (NASDAQ:TRVN) has earned a consensus rating of “Buy” from the thirteen ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $11.60.

TRVN has been the topic of several research reports. ValuEngine downgraded shares of Trevena from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Zacks Investment Research downgraded shares of Trevena from a “hold” rating to a “sell” rating in a report on Wednesday, July 26th. Oppenheimer Holdings, Inc. set a $8.00 price objective on shares of Trevena and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, Cowen and Company restated a “buy” rating and set a $10.00 price objective on shares of Trevena in a report on Friday, August 4th.

Trevena (NASDAQ TRVN) opened at 2.51 on Friday. Trevena has a 52-week low of $2.15 and a 52-week high of $8.00. The company’s market cap is $149.84 million. The company has a 50-day moving average of $2.44 and a 200-day moving average of $2.92.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.35). On average, equities research analysts expect that Trevena will post ($1.41) earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. American International Group Inc. grew its stake in shares of Trevena by 7.1% in the 1st quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 1,816 shares in the last quarter. Nationwide Fund Advisors grew its stake in shares of Trevena by 92.1% in the 2nd quarter. Nationwide Fund Advisors now owns 49,132 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 23,557 shares in the last quarter. Bourgeon Capital Management LLC grew its stake in shares of Trevena by 56.8% in the 2nd quarter. Bourgeon Capital Management LLC now owns 53,031 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 19,200 shares in the last quarter. Alliancebernstein L.P. grew its stake in shares of Trevena by 51.9% in the 2nd quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 18,900 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in shares of Trevena by 81.0% in the 1st quarter. SG Americas Securities LLC now owns 35,926 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 16,079 shares in the last quarter. Hedge funds and other institutional investors own 60.13% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Trevena, Inc. (TRVN) Given Consensus Recommendation of “Buy” by Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/09/16/trevena-inc-trvn-given-consensus-recommendation-of-buy-by-analysts.html.

About Trevena

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.